A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Inclusion Criteria: * Confirmed diagnosis of advanced solid tumor, recurrent or refractory medulloblastoma or locally advanced or metastatic basal cell carcinoma) * Protocol defined laboratory parameters * Performance status ≤ 2 * Patients must have fully recovered from the prior effects of major surgery and from any acute toxicities of prior chemotherapy/radiotherapy Exclusion Criteria: * History of central nervous system tumors of symptomatic brain metastases (excludes medulloblastoma patients) * Impairment of gastrointestinal function or unresolved nausea, vomiting or diarrhea * Impairment of cardiac function or significant cardiac disease * Pregnant or lactating women * Other protocol-defined inclusion/exclusion criteria may apply